Loading
A phase 3 trial of Cisplatin, Gemcitabine, Gemcitabine + cisplatin and Durvalumab in biliary tract cancer, run by Akeso, active and no longer recruiting.
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT06591520 by Akeso, with 682 participants enrolled, started 2024-10-20 and due to reach its primary completion in 2026-10. Interventions recorded: AK112, Gemcitabine, Cisplatin and Durvalumab, Gemcitabine, Cisplatin.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Durvalumab, Gemcitabine, Platinum agents, Cisplatin and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.